
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell RNA sequencing dataset of breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **CPB1 (Carboxypeptidase B1)**: Typically associated with pancreatic function, but its role in breast tissue is less clear.<br>- **IGFBP5 (Insulin-like Growth Factor Binding Protein 5)**: Involved in cell growth, apoptosis, and is known to be expressed in breast tissue.<br>- **GRIA2 (Glutamate Ionotropic Receptor AMPA Type Subunit 2)**: Generally associated with neural tissues, but can be involved in signaling pathways in other tissues.<br>- **GDF15 (Growth Differentiation Factor 15)**: A stress response cytokine, often upregulated in cancerous tissues.<br>- **CTSK (Cathepsin K)**: A protease involved in bone resorption, but also expressed in some cancer types.<br>- **GATA3 (GATA Binding Protein 3)**: A transcription factor critical for luminal cell differentiation in the breast.<br>- **ESR1 (Estrogen Receptor 1)**: A key receptor in breast tissue, particularly in luminal epithelial cells.<br><br>### Step 2: List the Key Cell Type Markers<br>- **GATA3**: Strongly associated with luminal epithelial cells in the breast.<br>- **ESR1**: Indicative of hormone receptor-positive breast cancer cells, typically luminal epithelial cells.<br>- **SCGB3A1 (Secretoglobin Family 3A Member 1)**: Known to be expressed in breast tissue, particularly in luminal cells.<br>- **AGR3 (Anterior Gradient 3)**: Associated with secretory epithelial cells in the breast.<br>- **SLC39A6 (Zinc Transporter)**: Often expressed in breast cancer cells, particularly luminal subtypes.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and literature on breast cancer scRNA-seq, we can confirm that markers like GATA3, ESR1, and SCGB3A1 are highly indicative of luminal epithelial cells in breast tissue.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of GATA3, ESR1, and SCGB3A1, the most probable general cell type is **luminal epithelial cells**. These markers are characteristic of cells that line the ducts and lobules of the breast and are often involved in hormone receptor-positive breast cancers.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Luminal A Subtype**: Characterized by high expression of hormone receptors like ESR1 and GATA3, typically associated with a better prognosis.<br>2. **Luminal B Subtype**: Also expresses ESR1 and GATA3 but may have higher proliferation markers and lower expression of hormone receptors compared to Luminal A.<br>3. **Normal Luminal Epithelial Cells**: Non-cancerous luminal cells that express GATA3 and ESR1, involved in normal breast tissue function.<br><br>The most likely subtype based on the markers is the **Luminal A Subtype**, given the high expression of ESR1 and GATA3, which are hallmark features of this subtype.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of luminal epithelial cells. The expression of key markers such as GATA3, ESR1, and SCGB3A1 strongly indicates a luminal phenotype, with the Luminal A subtype being the most probable due to the high expression of hormone receptors. This subtype is typically associated with a better prognosis in breast cancer.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency**:<br>   - The key markers used for annotation, such as GATA3, ESR1, and SCGB3A1, are present in the provided marker list.<br>   - These markers are well-known indicators of luminal epithelial cells in breast tissue, particularly in the context of breast cancer.<br><br>2. **Mixed Cell Type Consideration**:<br>   - The analysis does not strongly suggest the presence of multiple distinct cell types. The markers used are consistent with a single cell type, specifically luminal epithelial cells.<br>   - The annotation correctly identifies the Luminal A subtype as the most probable, based on the expression of hormone receptors like ESR1 and GATA3.<br><br>Overall, the annotation aligns well with the known biology of breast cancer and the provided marker list, supporting the conclusion of luminal epithelial cells, particularly the Luminal A subtype.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">luminal epithelial cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Luminal A Subtype</li><li>Luminal B Subtype</li><li>Normal Luminal Epithelial Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">85</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a strong understanding of the key markers associated with breast cancer, particularly luminal epithelial cells. The analysis correctly identifies GATA3, ESR1, and SCGB3A1 as critical markers for luminal epithelial cells, which are indeed well-documented in the context of breast cancer. The focus on these markers is appropriate given their prominence in the dataset and their biological relevance to the cell type in question.<br><br>The annotation process is thorough, with a clear step-by-step approach that includes listing functional markers, identifying key cell type markers, and cross-referencing with known databases. This methodical approach ensures that the annotation is grounded in scientific evidence and aligns with current understanding in the field.<br><br>However, there are a few areas where the analysis could be improved. While the focus on luminal epithelial cells is justified, the analysis could benefit from a more detailed exploration of other potential cell types or subtypes that might be present, even if they are less prominent. For instance, the presence of markers like GRIA2 and CTSK, which are not typically associated with luminal epithelial cells, could suggest the presence of other cell types or states that were not fully explored.<br><br>Additionally, while the annotation history mentions the rank of markers, it does not explicitly discuss how the rank influenced the final annotation. A more explicit consideration of the rank could provide additional insights into the relative importance of each marker in the dataset.<br><br>Overall, the annotation is scientifically accurate and provides a comprehensive view of the luminal epithelial cell population, particularly the Luminal A subtype. However, a more balanced consideration of all markers and potential mixed cell types could enhance the analysis.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    